Corbus Pharmaceuticals
CRBP
77 hedge funds and large institutions have $166M invested in Corbus Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 17 closing their positions.
45% more capital invested
Capital invested by funds: $114M → $166M (+$51.3M)
27% more call options, than puts
Call options by funds: $3.64M | Put options by funds: $2.86M
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.14% less ownership
Funds ownership: 1.42% → 1.28% (-0.14%)
6% less funds holding
Funds holding: 82 → 77 (-5)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.77M |
| 2 |
SC
Sculptor Capital
New York
|
+$1.62M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$1.41M |
| 4 |
Morgan Stanley
New York
|
+$947K |
| 5 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$803K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.25M |
| 3 |
Renaissance Technologies
New York
|
-$842K |
| 4 |
NC
Nexthera Capital
New York
|
-$678K |
| 5 |
Millennium Management
New York
|
-$662K |
CRBP Hedge Fund Activity: Q3 2018 in Review
77 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2018, worth a combined $166M — up 45% from $114M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CRBP and 12 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 24 added.
The largest buyer was BlackRock, adding an estimated $6.77M. The largest seller was Fidelity Investments, cutting an estimated $11.6M.
- 77 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2018, down from 82 in Q2 2018.
- Funds reported $166M of Corbus Pharmaceuticals stock for Q3 2018, up 45% quarter-over-quarter.
- 12 funds opened new Corbus Pharmaceuticals positions in Q3 2018 and 17 closed out, a net change of -5 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2018 was BlackRock, an estimated $6.77M added.
- The largest Corbus Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $11.6M sold.
Based on aggregated 13F filings for Q3 2018.